keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable stent

keyword
https://www.readbyqxmd.com/read/29455763/low-major-adverse-cardiac-event-rates-following-bioresorbable-vascular-scaffold-implantation-impact-of-implantation-technique-on-treatment-outcomes
#1
Anne Venkata Ganeshkumar, Rushikesh Sambhaji Patil, Irfan Khan Hamid
BACKGROUND AND OBJECTIVE: Studies conducted across the world have reported that the rates of major adverse cardiac events (MACE) following the use of bioresorbable vascular scaffolds (BVS) are comparable to that noted with traditional drug eluting stents (DES). However, there is limited data on the immediate and medium-term clinical outcomes following the use of the Absorb BVS (Abbott Vascular, Santa Clara, SA) in the Indian context. This study was conducted to determine real-world evidence on the immediate and medium-term clinical outcomes in all patients undergoing percutaneous coronary intervention (PCI) with the Absorb BVS...
January 2018: Indian Heart Journal
https://www.readbyqxmd.com/read/29447787/rationale-and-design-of-the-comparison-between-a-p2y12-inhibitor-monotherapy-versus-dual-antiplatelet-therapy-in-patients-undergoing-implantation-of-coronary-drug-eluting-stents-smart-choice-a-prospective-multicenter-randomized-trial
#2
Young Bin Song, Seok Kyu Oh, Ju-Hyeon Oh, Eul-Soon Im, Deok-Kyu Cho, Byung Ryul Cho, Jong-Young Lee, Joo Myung Lee, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuck Choi, Sang Hoon Lee, Hyeon-Cheol Gwon, Joo-Yong Hahn
BACKGROUND AND RATIONALE: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. It is unclear whether P2Y12 inhibitor monotherapy might maintain anti-ischemic efficacy while reducing the bleeding risk compared with DAPT after implantation of the current generation of drug-eluting stents (DES)...
March 2018: American Heart Journal
https://www.readbyqxmd.com/read/29435779/therapeutic-options-for-in-stent-restenosis
#3
REVIEW
Charles Nicolais, Vladimir Lakhter, Hafeez Ul Hassan Virk, Partha Sardar, Chirag Bavishi, Brian O'Murchu, Saurav Chatterjee
PURPOSE OF REVIEW: In-stent restenosis (ISR) is a complex disease process that became apparent shortly after the introduction of stents into clinical practice. This review seeks to define in-stent restenosis (ISR) as well as to summarize the major treatment options that have been developed and studied over the past two decades. RECENT FINDINGS: Recent developments in drug-coated balloons and bioresorbable vascular scaffolds have added new potential treatments for ISR...
February 12, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29426631/outcomes-of-a-novel-thin-strut-bioresorbable-polymer-sirolimus-eluting-stent-in-patients-with-chronic-total-occlusions-a-multicenter-registry
#4
Lorenzo Azzalini, Ozan M Demir, Gabriele L Gasparini, Luca Grancini, Alessio La Manna, Soledad Ojeda, Susanna Benincasa, Barbara Bellini, Enrico Poletti, Davide Maccagni, Margherita Soldi, Loredana Iannetta, Daniela Trabattoni, Giacomo Gravina, Francisco Hidalgo, Francesco Giannini, Manuel Pan, Corrado Tamburino, Antonio L Bartorelli, Bernhard Reimers, Cosmo Godino, Mauro Carlino, Antonio Colombo
BACKGROUND: We aimed to evaluate the mid-term outcomes of a novel thin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES) in chronic total occlusion (CTO) percutaneous coronary intervention (PCI), as compared with durable-polymer everolimus-eluting stents (EES). METHODS: We compiled a multicenter registry of patients undergoing CTO recanalization followed by BP-SES or EES implantation. The primary endpoint was the incidence of target-lesion failure (TLF, a composite of cardiac death, target-vessel myocardial infarction, and target-lesion revascularization) at one year...
January 31, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29415486/impact-of-psp-technique-on-clinical-outcomes-following-bioresorbable-scaffolds-implantation
#5
REVIEW
Luis Ortega-Paz, Salvatore Brugaletta, Manel Sabaté
Bioresorbable scaffolds (BRS) were introduced in clinical practice to overcome the long-term limitations of newer-generation drug-eluting stents. Despite some initial promising results of the Absorb BRS, safety concerns have led to the discontinuation of the commercialization of this device. Several retrospective studies have assessed the impact of the so-called Pre-dilation, Sizing and Post-dilation (PSP) technique concluding that an optimal PSP technique can improve clinical outcomes following BRS implantation...
February 6, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29413240/a-randomized-trial-comparing-the-neovas-sirolimus-eluting-bioresorbable-scaffold-and-metallic-everolimus-eluting-stents
#6
Yaling Han, Bo Xu, Guosheng Fu, Xiaozeng Wang, Kai Xu, Chongying Jin, Ling Tao, Lang Li, Yuqing Hou, Xi Su, Quan Fang, Lianglong Chen, Huiliang Liu, Bin Wang, Zuyi Yuan, Chuanyu Gao, Shenghua Zhou, Zhongwei Sun, Yanyan Zhao, Changdong Guan, Gregg W Stone
OBJECTIVES: The authors sought to evaluate the safety and effectiveness of the NeoVas bioresorbable scaffold (BRS) compared with metallic drug-eluting stents. BACKGROUND: BRS have the potential to improve very late outcomes compared with metallic drug-eluting stents, but some BRS have been associated with increased rates of device thrombosis before complete bioresorption. NeoVas is a new poly-l-lactic acid BRS that elutes sirolimus from a poly-D, l-lactide coating...
February 12, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29399773/deciphering-bioresorbable-stent-thrombosis-investigating-the-mechanisms
#7
Nicholas G Kounis, Grigorios Tsigkas, Ioanna Koniari, George Tzanis, Stefanos Despotopoulos, Anastasios Roumeliotis, George Hahalis
No abstract text is available yet for this article.
2018: Kardiologia Polska
https://www.readbyqxmd.com/read/29398632/transradial-experience-with-bioresorbable-vascular-scaffolds-a-case-matched-study-with-metallic-drug-eluting-stents
#8
Frédéric Maes, Olivier Costerousse, Tomas Cieza, Mélaine Henry, Jean-Pierre Déry, Gérald Barbeau, Robert Delarochellière, Jean-Michel Paradis, Eric Larose, Can M Nguyen, Charles Pirlet, Rosaire Mongrain, Olivier F Bertrand
BACKGROUND: Whether polymeric bioresorbable vascular scaffolds (BVS) implantation with transradial approach is feasible and safe is unknown. We compared the feasibility and safety of the transradial approach for BVS delivery with metallic drug-eluting stents (DES). METHODS: We identified 118 consecutive patients who underwent BVS implantation and we compared 30-days and 1-year results with 118 matched patients with DES. Patients were matched for age, sex, risk factors and clinical indication...
January 6, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29372810/treatment-of-coronary-bifurcation-lesions-current-knowledge-and-future-perspectives
#9
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
Coronary lesions at bifurcation sites are frequent and still remain a challenging subset for the interventional cardiologist. Although in the last years the provisional stenting technique has shown more consistent results, coronary bifurcation interventions still share a worse procedural success rate and increased rates of mid- and long-term cardiac events. Most of the dedicated devices proposed in the last few years have failed to show improved results when compared with standard devices. The broader use of imaging techniques, such as intravascular ultrasound and optical coherence tomography, lead to a better understanding of the real anatomy of bifurcations and has shown to be a great tool for percutaneous coronary intervention optimization...
January 26, 2018: Future Cardiology
https://www.readbyqxmd.com/read/29370208/coronary-magnetic-resonance-imaging-after-routine-implantation-of-bioresorbable-vascular-scaffolds-allows-non-invasive-evaluation-of-vascular-patency
#10
Constantin von Zur Mühlen, Simon Reiss, Axel J Krafft, Lisa Besch, Marius Menza, Manfred Zehender, Timo Heidt, Alexander Maier, Thomas Pfannebecker, Andreas Zirlik, Jochen Reinöhl, Peter Stachon, Ingo Hilgendorf, Dennis Wolf, Philipp Diehl, Tobias Wengenmayer, Ingo Ahrens, Christoph Bode, Michael Bock
BACKGROUND: Evaluation of recurrent angina after percutaneous coronary interventions is challenging. Since bioresorbable vascular scaffolds (BVS) cause no artefacts in magnetic resonance imaging (MRI) due to their polylactate-based backbone, evaluation of vascular patency by MRI might allow for non-invasive assessment and triage of patients with suspected BVS failure. METHODS: Patients with polylactate-based ABSORB-BVS in proximal coronary segments were examined with 3 Tesla MRI directly (baseline) and one year after implantation...
2018: PloS One
https://www.readbyqxmd.com/read/29356269/bioresorbable-vascular-scaffold-versus-everolimus-eluting-stents-or-drug-eluting-balloon-for-the-treatment-of-coronary-in-stent-restenosis-1-year-follow-up-of-a-propensity-score-matching-comparison-the-bioresolve-isr-study
#11
Elisabetta Moscarella, Akihito Tanaka, Alfonso Ielasi, Bernardo Cortese, Sebastian Coscarelli, Maria Carmen De Angelis, Davide Piraino, Azeem Latib, Giulietta Grigis, Renatomaria Bianchi, Dario Buccheri, Paolo Calabrò, Maurizio Tespili, Pedro Silva Orrego, Antonio Colombo, Attilio Varricchio
OBJECTIVES: to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. BACKGROUND: BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. METHODS: We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014...
January 22, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29349686/two-year-results-after-coronary-stenting-of-small-vessels-in-japanese-population-using-2-25-mm-diameter-sirolimus-eluting-stent-with-bioresorbable-polymer-primary-and-long-term-outcomes-of-century-jsv-study
#12
Shigeru Saito, Kenji Ando, Yoshiaki Ito, Tetsuya Tobaru, Junji Yajima, Takeshi Kimura, Kazushige Kadota
Percutaneous coronary intervention (PCI) in coronary artery disease (CAD) with very small vessels remains challenging. The aim of this study is to evaluate the safety and effectiveness of the 2.25-mm diameter Ultimaster sirolimus-eluting stent in the treatment of Japanese patients with CAD due to lesions in very small vessels. The CENTURY JSV study is a prospective, multicentre, single-arm study. Seventy patients with lesions deemed suitable for implantation of a 2.25-mm diameter stent were enrolled at seven hospitals in Japan...
January 18, 2018: Cardiovascular Intervention and Therapeutics
https://www.readbyqxmd.com/read/29339714/stent-thrombosis-in-patients-with-drug-eluting-stents-and-bioresorbable-vascular-scaffolds-the-feared-complication
#13
Laura S Kerkmeijer, Erhan Tenekecioglu, Joanna J Wykrzykowska
The percutaneous coronary intervention has undergone rapid evolution over the last 40 years and has become one of the most widely performed medical procedures. The introduction of intracoronary stents improved the safety and efficacy of percutaneous coronary intervention. But with the advent of stenting, a new potentially fatal enemy emerged: stent thrombosis. Ever since, adjunct pharmacological therapy, stent technique and technology have been adjusted to reduce the risk of stent thrombosis. The aim of the present article is to provide an overview of past, present and future aspects of percutaneous intervention in relation to stent thrombosis...
January 15, 2018: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29332307/scaffold-thrombosis-following-implantation-of-the-absorb-bvs-in-routine-clinical-practice-insight-into-possible-mechanisms-from-optical-coherence-tomography
#14
Robin P Kraak, Alexandre H Kajita, Hector M Garcia-Garcia, Jose P S Henriques, Jan J Piek, E Karin Arkenbout, René J van der Schaaf, Jan G P Tijssen, Robbert J de Winter, Joanna J Wykrzykowska
OBJECTIVES: To identify potential underlying mechanisms of early and (very) late scaffold thrombosis (ScT) by optical coherence tomography (OCT), in a frame-by-frame analysis. BACKGROUND: The absorb scaffold is associated with an increased risk of ScT compared with metallic stents. Several potential causes of bioresorbable ScT have been identified, however the precise etiology still remains unclear. METHODS: Between February 2013 and February 2016, 13 patients presenting with definite ScT underwent OCT imaging...
January 14, 2018: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/29327860/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#15
Robin P Kraak, Joanna J Wykrzykowska
No abstract text is available yet for this article.
November 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327859/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#16
Ron Waksman
No abstract text is available yet for this article.
November 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327858/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#17
Corrado Tamburino, Piera Capranzano
No abstract text is available yet for this article.
November 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29327857/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#18
Gian-Battista Danzi, Raffaele Piccolo
No abstract text is available yet for this article.
November 2, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29326152/decision-analytic-markov-model-weighting-expected-benefits-and-current-limitations-of-first-generation-bioresorbable-vascular-scaffolds-implications-for-manufacturers-and-next-device-iterations
#19
Davide Capodanno, Sergio Buccheri, Sara Romano, Piera Capranzano, Bruno Francaviglia, Corrado Tamburino
BACKGROUND: Relative benefits of bioresorbable vascular scaffolds (BVS) compared with everolimus-eluting stents (EES) are expected to accrue after complete bioresorption. METHODS AND RESULTS: We built a decision analytic Markov model comparing BVS and EES for a contemporary percutaneous coronary intervention population. Procedure-related morbidity and outcome data from the available literature were used to derive model probabilities. The net benefit of BVS and EES was estimated in terms of quality-adjusted life expectancy...
January 2018: Circulation. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29322695/bioresorbable-scaffolds-in-coronary-intervention-unmet-needs-and-evolution
#20
REVIEW
Davide Capodanno
Bioresorbable scaffolds (BRS) represent a novel paradigm in the 40-year history of interventional cardiology. Restoration of cyclic pulsatility and physiologic vasomotion, adaptive vascular remodeling, plaque regression, and removal of the trigger for late adverse events are expected BRS benefits over current metallic drug-eluting stents. However, first-generation BRS devices have significant manufacturing limitations and rely on optimal implantation technique to avoid experiencing an excess of clinical events...
January 2018: Korean Circulation Journal
keyword
keyword
116611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"